Skip to main content

Main menu

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
      • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising
  • BMJ Journals

User menu

  • Login

Search

  • Advanced search
  • BMJ Journals
  • Login
  • Facebook
  • Twitter
JIM

Advanced Search

  • Online first
    • Online first
  • Current issue
    • Current issue
  • Archive
    • Archive
  • Submit a paper
    • Online submission site
    • Information for authors
  • About the journal
    • About the journal
    • Editorial board
    • Information for authors
    • FAQs
    • Thank you to our reviewers
    • American Federation for Medical Research
  • Help
    • Contact us
    • Feedback form
    • Reprints
    • Permissions
    • Advertising

Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19

Simrat Kaur Batth
DOI: 10.1136/jim-2021-001881 Published 26 July 2021
Simrat Kaur Batth
Punjab Institute of Medical Sciences, Jalandhar, Punjab, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Simrat Kaur Batth
  • Article
  • eLetters
  • Info & Metrics
  • PDF
Loading

Dear Editor,

I have read the study “ALLY in fighting COVID-19: magnitude of albumin decline and lymphopenia (ALLY) predict progression to critical disease”1 with great interest but would like to bring some issues to the notice of the readers.

First, the study used a comorbidity score to calculate the number of comorbidities present at admission out of asthma, coronary artery disease, chronic obstructive pulmonary disease, diabetes mellitus, hypertension, cancer, history of renal disease, and smoking.1 ⁠ Liver disease has not been considered in the comorbidity scale, which can greatly influence the albumin level at any given time and the rate of its decline.

Second, systemic inflammation is common in severe COVID-19. Inflammation has been shown to cause the escape of serum albumin into the interstitial space due to increased capillary permeability, and eventually lead to increased volume distribution of albumin.2 ⁠ Interleukin 6 (IL-6) contributes to vascular hyperpermeability, leakiness, hypotension, and pulmonary dysfunction.3 The study could not correlate the magnitude and the rate of albumin change with inflammatory biomarkers such as C-reactive protein (CRP) or IL-6 which were not consistently available over the course of admission.1 ⁠⁠ This means that the study could not make a conclusion that the albumin decline of 0.9 g/dL or greater within 5 days of admission was solely due to COVID-19-induced inflammatory state. Correlating the albumin level with CRP and IL-6 would have helped to rule out the effect of comorbidities and confounders which might have affected albumin levels.

Third, the study mentions that the analysis was performed at the time when steroids were discouraged by the WHO guidelines,1 so considering an albumin drop of 0.9 g/dL or greater within 5 days of admission as a factor for higher risk of disease progression might not be correct at present due to the availability of various treatment options such as corticosteroids and IL-6 inhibitors that suppress cytokine storm.4 ⁠⁠ The effect of such drugs on albumin level in patients with COVID-19 needs to be investigated as they might have an effect on the rate of albumin decline.

Ethics statements

Patient consent for publication

Not required.

Footnotes

  • Contributors SKB, being the sole author, is responsible for the preparation of the entire manuscript.

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.

This article is made freely available for use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.

https://bmj.com/coronavirus/usage

References

  1. ↵
    1. van Zyl JS ,
    2. Alam A ,
    3. Felius J , et al
    . Ally in fighting COVID-19: magnitude of albumin decline and lymphopenia (ally) predict progression to critical disease. J Investig Med 2021;69:710–8.doi:10.1136/jim-2020-001525 pmid:http://www.ncbi.nlm.nih.gov/pubmed/33431604
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Huang J ,
    2. Cheng A ,
    3. Kumar R , et al
    . Hypoalbuminemia predicts the outcome of COVID-19 independent of age and co-morbidity. J Med Virol 2020;92:2152–8.doi:10.1002/jmv.26003 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32406952
    OpenUrlPubMed
  3. ↵
    1. Fajgenbaum DC ,
    2. June CH
    . Cytokine storm. N Engl J Med 2020;383:2255–73.doi:10.1056/NEJMra2026131 pmid:http://www.ncbi.nlm.nih.gov/pubmed/33264547
    OpenUrlCrossRefPubMed
  4. ↵
    1. Miao Y ,
    2. Fan L ,
    3. Li J-Y
    . Potential Treatments for COVID-19 Related Cytokine Storm - Beyond Corticosteroids. Front Immunol 2020;11:1445. doi:10.3389/fimmu.2020.01445 pmid:http://www.ncbi.nlm.nih.gov/pubmed/32612616
    OpenUrlCrossRefPubMed
PreviousNext
Back to top
Vol 69 Issue 6 Table of Contents
Journal of Investigative Medicine: 69 (6)
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • AFMR Highlights
  • Front Matter (PDF)
Email

Thank you for your interest in spreading the word on JIM.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
(Your Name) has sent you a message from JIM
(Your Name) thought you would like to see the JIM web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Print
Alerts
Sign In to Email Alerts with your Email Address
Citation Tools
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
Simrat Kaur Batth
Journal of Investigative Medicine Aug 2021, 69 (6) 1259; DOI: 10.1136/jim-2021-001881

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Cite This
  • APA
  • Chicago
  • Endnote
  • MLA
Loading
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
Simrat Kaur Batth
Journal of Investigative Medicine Aug 2021, 69 (6) 1259; DOI: 10.1136/jim-2021-001881
Download PDF

Share
Correlation of rate of serum albumin decline with other acute phase reactants and effect of current treatment options on serum albumin level in COVID-19
Simrat Kaur Batth
Journal of Investigative Medicine Aug 2021, 69 (6) 1259; DOI: 10.1136/jim-2021-001881
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Respond to this article
  • Tweet Widget
  • Facebook Like
  • Google Plus One
  • Article
    • Ethics statements
    • Footnotes
    • References
  • eLetters
  • Info & Metrics
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Correspondence on ‘Prospective predictive performance comparison between clinical gestalt and validated COVID-19 mortality scores’ by Soto-Mota et al
  • Response to: Correspondence on ‘Prospective predictive performance comparison between clinical gestalt and validated COVID-19 mortality scores’ by Meza-Comparán
  • Estimating clinical research project duration from idea to publication
Show more Letter to the editor

Similar Articles

 

CONTENT

  • Latest content
  • Current issue
  • Archive
  • Sign up for email alerts
  • RSS

JOURNAL

  • About the journal
  • Editorial board
  • Subscribe
  • Thank you to our reviewers
  • American Federation for Medical Research

AUTHORS

  • Information for authors
  • Submit a paper
  • Track your article
  • Open Access at BMJ

HELP

  • Contact us
  • Reprints
  • Permissions
  • Advertising
  • Feedback form

© 2022 American Federation for Medical Research